表紙
市場調査レポート

世界のジェネリック医薬品市場:アジア市場

Generic Drugs: The Global Market--Focus on Asia

発行 BCC Research 商品コード 210430
出版日 ページ情報 英文 161 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
世界のジェネリック医薬品市場:アジア市場 Generic Drugs: The Global Market--Focus on Asia
出版日: 2011年09月08日 ページ情報: 英文 161 Pages
概要

当レポートでは、世界およびアジアの後発医薬品市場について調査分析し、2010年の実績と2016年までの市場予測、業界構造、主要企業のプロファイルなどをまとめ、概略下記の構成でお届けいたします。

第1章 イントロダクション

第2章 サマリー

第3章 概要

  • 近年のジェネリック医薬品部門の歴史

第4章 新しいジェネリック医薬品の時代

  • 特許失効
  • ジェネリック医薬品の種類
    • "シンプル"ジェネリック医薬品
    • スーパージェネリック医薬品
    • バイオシミラー
  • 主な課題
    • 法規制環境
    • バイオシミラーの規制
    • "承認済みジェネリック医薬品"
  • 特許と知的財産

第5章 世界の医薬品およびジェネリック医薬品市場

  • 世界のジェネリック医薬品市場
  • 主要国市場
  • 製品クラスベル市場の機会

第6章 アジア市場

  • 日本
    • 重要統計
    • 健康と医療
    • 医薬品市場
    • ジェネリック医薬品部門
  • インド
    • 重要統計
    • 健康と医療
    • 医薬品市場
    • ジェネリック医薬品部門
  • 中国
    • 重要統計
    • 健康と医療
    • 医薬品市場
    • ジェネリック医薬品部門

第7章 ジェネリック医薬品メーカー10社のプロファイル

  • 動向
  • ジェネリック医薬品業界構造
  • ジェネリック医薬品メーカー10社のプロファイル
    • Actavis
    • Apotex Inc.
    • Dr. Reddy's laboratories, Ltd.
    • Hospira, Inc.
    • Mylan Inc.
    • Par Pharmaceutical, Inc.
    • Ranbaxy Laboratories, Ltd.
    • Sandoz International GmbH
    • Teva Pharmaceutical Industries, Ltd.
    • Watson Pharmaceuticals, Inc.

第8章 その他のメーカープロファイル

第18章 付録

目次
Product Code: PHM108A

Abstract

REPORT HIGHLIGHTS

THIS REPORT CONTAINS

  • An examination of the strategies employed by companies specializing in generics to meet the challenges of this highly competitive market as well as those utilized by "originator" companies to forestall generic competition; this report will focus on the markets in Asia
  • Analyses of market trends, with data from 2010, estimates for 2011, and projections of compound annual growth rates (CAGRs) through 2016
  • Discussion of how fierce price competition has put some companies in difficulties because of slashed profit margins, and of the resulting wave of merger-and-acquisition activity, and the rise of "supergenerics" that offer added value as well as low prices
  • A breakdown of the nature and structure of the generics industry, with profiles of several leading generics companies, and an update of M&A activity
  • Patent analyses.

image1

REPORT SCOPE

INTRODUCTION

STUDY GOALS AND OBJECTIVES

The aim of this report is to provide detailed market, technology, and industry analyses to help readers quantify and qualify the market for prescription generic drugs. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2016; these are based on industry sources and considered assessment of the regulatory environment, healthcare policies, demographics, and other factors that directly affect the generic drug market. The wider economic environment is also taken into account.

The report examines strategies employed by companies specializing in generics to meet the challenges of this highly competitive market, while also summarizing strategies employed by "originator" companies to forestall generic competition.

REASONS FOR DOING THE STUDY

This is a time of growth and change for the generic pharmaceuticals sector. Major aspects that combine to create an opportunity for an up-to-date market analysis include the following:

  • The demand for generics is increasing steadily because of pressure to control healthcare costs. At the same time, fierce price competition in this area has created difficulties for some companies because of slashed profit margins. The main result has been a wave of merger and acquisition (M&A) activity, and the rise of "supergenerics," offering added value as well as low prices. Not all traditional companies are positioned to exploit this trend.
  • A major growth driver for the generics sector is the fact that several blockbuster pharmaceutical brands are coming off-patent and are therefore open to generic competition - the phenomenon widely known as the "patent cliff." But the originator companies are deploying formidable strategies to protect their franchises, including marketing their own branded generics.
  • With first-generation biopharmaceutical products reaching the end of their patent lives, a whole new market field - biogenerics or biosimilars - is opening up for those generics companies capable of (or prepared to buy-into) the technological expertise required.
  • The international landscape is changing for generics as for all pharmaceuticals. China, India, Russia, Mexico, and Brazil are among the rising markets for generic activity.

SCOPE OF REPORT

This report discusses the implications of all the above-mentioned trends, in the context of the current size and growth of the generics market, both in global terms and analyzed by the most important national markets. The nature and structure of the generics industry is discussed, with profiles of the leading 20+ generics companies, and an update on M&A activity. Five-year sales forecasts are provided for the national markets and the major therapeutic categories of products involved.

The report presents overall market size estimates and analysis for the overall global market, as well as more detailed market coverage of the three major segments of the global market: the American market, the European market, and the Asian market. The American market coverage focuses on the largest markets of North and Latin America (the U.S., Canada, Brazil, and Mexico); European market coverage focuses on the markets in France, Germany, Italy, Spain, and the United Kingdom, as well as an analysis of the Russian market; and Asia market coverage focuses on the three major markets of Japan, China, and India.

MARKET ANALYSES AND FORECASTS

Market figures are based on revenues at the manufacturer level and are projected based on 2011 dollar value without attempting to predict the effect of inflation/deflation. Therapeutic categories quantified and forecast include antibacterials, antidepressants, anticancer agents, anti-arthritics, cardiovascular drugs (e.g., hypolipidaemics and antihypertensives), and drugs for respiratory conditions, including asthma and COPD.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. Primary research includes interviews with leading individuals in generics companies, industry associations, and regulatory bodies. Sources of published data include company annual reports, SEC filings, government and industry publications, literature searches, industry journals, and other commercial publications. Data for market estimates and forecasts are pooled from a range of sources, and are critically assessed by BCC Research.

INTENDED AUDIENCE

This report is designed to satisfy the information needs of a wide variety of individuals involved in the generics marketplace, including company senior management executives seeking to base their strategic decisions on the best available information on market forces and trends. However, it is also aimed at managers and executives in marketing, research, planning, and sales departments who need readable, comprehensive, and up-to-date background on the marketplace in which they are operating.

INFORMATION SOURCES

Sources of information included marketing strategists, industry executives, government agencies and regulatory bodies, and surveys of physicians and pharmacists. Company annual reports and SEC filings, journal articles, and data from healthcare institutions were also mined, as well as publications of relevant trade associations such as the Generic Pharmaceutical Association (GPhA) and the European Generic Medicines Association (EGA).

ANALYST CREDENTIALS

Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of two previous reports on the generics marketplace as well as analyses of major therapeutic categories and the pharmaceutical regulatory environment.

Table of Contents

Chapter- 1: INTRODUCTION - Complimentary

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • MARKET ANALYSES AND FORECASTS
  • METHODOLOGY
  • INTENDED AUDIENCE
  • INFORMATION SOURCES
  • ANALYST CREDENTIALS
  • RELATED REPORTS
  • BCC ONLINE SERVICES
  • DISCLAIMER

Chapter- 2: SUMMARY

  • MARKET SIZE AND EVOLUTION
    • Table 0 : MAJOR GENERICS MARKETS, THROUGH 2016
    • Figure 0 : MAJOR GENERICS MARKETS, THROUGH 2016

Chapter- 3: OVERVIEW

  • RECENT HISTORY OF THE GENERICS SECTOR

Chapter- 4: THE NEW GENERICS ERA

  • THE PATENT CLIFF
  • TYPES OF GENERICS
  • MAJOR GENERIC ISSUES
  • PATENTS AND IP

Chapter- 5: THE GLOBAL PHARMACEUTICAL AND GENERICS MARKET

  • GLOBAL GENERICS MARKET
  • MAIN NATIONAL GENERICS MARKETS
  • MARKET OPPORTUNITIES BY PRODUCT CLASS

Chapter- 6: THE ASIAN REGION

  • JAPAN
  • INDIA
  • CHINA

Chapter- 7: PROFILES OF THE TOP TEN GENERICS COMPANIES

  • TRENDS
  • STRUCTURE OF THE GENERICS INDUSTRY
  • PROFILES OF TOP 10 GENERICS COMPANIES

Chapter- 8: PROFILES OF OTHER INTERNATIONAL GENERICS COMPANIES

  • PROFILES

List of Tables

  • Summary Table : MAJOR GENERICS MARKETS, THROUGH 2016
  • Table 1 : GLOBAL PHARMACEUTICAL AND GENERICS MARKETS, THROUGH 2016
  • Table 2 : FIRST PATENT EXPIRIES, 2012 - 2023
  • Table 3 : BIOLOGICS FACING THE LAUNCH OF BIOSIMILARS, 2001 - 2006
  • Table 4 : REQUIREMENTS FOR NDA AND ANDA APPLICATIONS
  • Table 5 : WORLD PHARMA AND GENERICS MARKETS, THROUGH 2016
  • Table 6 : CURRENT AND FORECAST NATIONAL GENERICS MARKETS, THROUGH 2016
  • Table 7 : WIDELY PRESCRIBED GENERIC MOLECULES IN THE U.S. AND EUROPE
  • Table 8 : LEADING ANTI-INFECTIVE PRODUCTS SALES ESTIMATES WITH YEAR OF PATENT EXPIRY, 2010
  • Table 9 : CNS MARKET BY MAJOR INDICATIONS, 2010
  • Table 10 : LEADING CNS PRODUCT SALES ESTIMATES, 2010
  • Table 11 : LEADING CARDIOVASCULAR PRODUCT SALES, 2009
  • Table 12 : LEADING ANTI-ARTHRITIS PRODUCT SALES ESTIMATES, 2009
  • Table 13 : LEADING RESPIRATORY PRODUCT SALES ESTIMATES, 2009
  • Table 14 : LEADING ANTICANCER PRODUCT SALES ESTIMATES, 2009
  • Table 15 : TOP 5 JAPANESE PHARMA COMPANIES, 2008
  • Table 16 : JAPANESE PHARMACEUTICAL AND GENERICS MARKET, 2011 - 2016
  • Table 17 : LEADING PHARMA COMPANIES IN INDIA, 2010
  • Table 18 : PHARMACEUTICAL AND GENERICS MARKET IN INDIA, THROUGH 2016
  • Table 19 : PHARMACEUTICAL AND GENERICS MARKET, CHINA, THROUGH 2016
  • Table 20 : LEADING GENERICS MANUFACTURERS, 2010
  • Table 21 : PFIZER' S U.S. PATENT EXPIRIES, THROUGH 2021

List of Figures

  • Summary Figure : MAJOR GENERICS MARKETS, THROUGH 2016
  • Figure 1 : CNS MARKET SHARES BY MAJOR INDICATIONS, 2010
  • Figure 2 : USAGE OF MAIN PRODUCT CATEGORIES BASED REVENUES
  • Figure 3 : GENERICS MARKET THERAPEUTIC CATEGORIES 2008
Back to Top